Holen Sie sich die Stockscreener-App
23.24
2.96%
-0.7451
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment - The Motley Fool
Avoiding Lag: Real-Time Signals in (SNDX) Movement - Stock Traders Daily
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026 - The Globe and Mail
Syndax Pharmaceuticals stock hits 52-week high at $22.91 By Investing.com - Investing.com Canada
JPMorgan Chase & Co. Increases Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $45.00 - MarketBeat
SNDX: JP Morgan Raises Price Target to $45Maintains Overweigh - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 1-Year HighStill a Buy? - MarketBeat
Wall Street Zen Upgrades Syndax Pharmaceuticals (NASDAQ:SNDX) to Hold - MarketBeat
Syndax Pharmaceuticals’ Earnings Call Highlights Growth Push - TipRanks
Can Syndax Pharmaceuticals Inc. stock maintain growth trajectory2026 Momentum Check & AI Forecasted Stock Moves - Naître et grandir
Syndax Pharmaceuticals, Inc. $SNDX is Knott David M Jr's 7th Largest Position - MarketBeat
Vanguard Group Inc. Buys 104,683 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Market Wrap: Is Syndax Pharmaceuticals Inc. forming a double bottomWeekly Trading Summary & Reliable Entry Point Alerts - baoquankhu1.vn
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Bitget
Syndax Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
How Investors May Respond To Syndax Pharmaceuticals (SNDX) Shelf Offering And Revuforj Niktimvo Momentum - Sahm
Syndax Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-03-03 - Seeking Alpha
Is Syndax Pharmaceuticals (SNDX) Pricing Reflect Pipeline Progress Or Stretching Recent Share Gains - simplywall.st
SNDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SNDX Receives Buy Rating as Citigroup Raises Price Target to $57 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $57.00 Price Target at Citigroup - MarketBeat
Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs - Bitget
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2025 Earnings Call Transcript - Insider Monkey
Syndax Pharmaceuticals Q4 Revenue Ramp To US$68.7 Million Tests Bullish Growth Narrative - simplywall.st
Barclays Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Syndax Pharmaceuticals (NASDAQ:SNDX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story? - Yahoo Finance
A Look At Syndax Pharmaceuticals (SNDX) Valuation After Q4 Revenue Beat And Wider Loss - simplywall.st
Syndax (SNDX) Q4 2025 Earnings Call Transcript - Intellectia AI
Syndax Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Syndax Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Discipline and Rules-Based Execution in SNDX Response - Stock Traders Daily
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Syndax Pharmaceuticals (SNDX) Reports Strong 2025 Earnings and Growth Prospects - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Earnings Results - MarketBeat
Syndax Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Syndax (SNDX) Projects Stable Operating Expenses and Path to Pro - GuruFocus
Syndax (SNDX) Exceeds Revenue Expectations, Anticipates Continued Growth - GuruFocus
Syndax Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Q4 2025 Syndax Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings Flash (SNDX) Syndax Pharmaceuticals, Inc. Reports Q4 Revenue $68.7M, vs. FactSet Est of $64.3M - marketscreener.com
BRIEF-Syndax Pharmaceuticals Q4 Operating Expenses USD 131.276 Million - TradingView
Cancer drug maker Syndax posts $172M sales, eyes profitability - Stock Titan
Syndax faces earnings test as cancer drug launches accelerate By Investing.com - Investing.com UK
Syndax faces earnings test as cancer drug launches accelerate - Investing.com India
Syndax: Overview of Fourth Quarter Financial Results - Bitget
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Syndax Pharmaceuticals, Inc. announces that patient enrollment has been completed for its Phase II clinical trial of Axatilimab for idiopathic pulmonary fibrosis (IPF). - Bitget
VIX Spike: Is Syndax Pharmaceuticals Inc stock showing strong momentumBull Run & High Yield Equity Trading Tips - baoquankhu1.vn
Syndax Announces Participation in March Investor Conferences - GlobeNewswire
Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Monday - Defense World
Aberdeen Group plc Grows Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Is Syndax Pharmaceuticals Inc. a speculative investment2025 Price Momentum & Accurate Trade Setup Notifications - mfd.ru
Earnings Miss: Does Syndax Pharmaceuticals Inc. have strong fundamentalsQuarterly Investment Review & Safe Capital Investment Plans - mfd.ru
Can Syndax Pharmaceuticals Inc. stock double in the next yearInsider Selling & Precise Trade Entry Recommendations - mfd.ru
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):